MusclePharm Chairman Flexes Financial Support, Board Influence
This article was originally published in The Tan Sheet
Executive Summary
Ryan Drexler buys a $6m promissory note bearing 8% annual interest, convertible to shares priced at $2.30, two months after committing $6.2m to guarantee existing bank loans for the sports nutrition firm.
You may also be interested in...
MusclePharm Sheds 75% Of Portfolio, Flexes After Spending Stretched It Thin
MusclePharm whittled its product line from 450 to 120 SKUs and is shifting its distribution focus in the US from specialty retail to Amazon and Costco. The firm also cut operating costs, spending $10m less in 2017 than in 2016.
AHPA Comments On Vinpocetine: Health And Wellness Industry News Roundup
AHPA argues FDA erred in vinpocetine proposal; and MusclePharm CEO bails out firm again.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.